Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | fibrosarcoma of bone |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | fibrosarcoma of bone | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive malignant histiocytosis (PMID: 31812554; NCT02332668). | 31812554 |
PubMed Id | Reference Title | Details |
---|---|---|
(31812554) | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Full reference... |